![]() |
Name |
Aspermicrone B
|
Molecular Formula | C19H18O10 | |
IUPAC Name* |
(1R,3R)-4,5,5',6,6',7'-hexahydroxy-1-methoxy-7,8'-dimethylspiro[1H-2-benzofuran-3,3'-1H-isochromene]-4'-one
|
|
SMILES |
CC1=C2CO[C@@]3(C4=C(C(=C(C(=C4[C@@H](O3)OC)C)O)O)O)C(=O)C2=C(C(=C1O)O)O
|
|
InChI |
InChI=1S/C19H18O10/c1-5-7-4-28-19(17(26)9(7)13(22)15(24)11(5)20)10-8(18(27-3)29-19)6(2)12(21)16(25)14(10)23/h18,20-25H,4H2,1-3H3/t18-,19-/m1/s1
|
|
InChIKey |
QMVOBCWDKWKDII-RTBURBONSA-N
|
|
Synonyms |
Aspermicrone B
|
|
CAS | NA | |
PubChem CID | 145720716 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 406.3 | ALogp: | 1.3 |
HBD: | 6 | HBA: | 10 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 166.0 | Aromatic Rings: | 4 |
Heavy Atoms: | 29 | QED Weighted: | 0.387 |
Caco-2 Permeability: | -5.969 | MDCK Permeability: | 0.00000413 |
Pgp-inhibitor: | 0.05 | Pgp-substrate: | 0.469 |
Human Intestinal Absorption (HIA): | 0.889 | 20% Bioavailability (F20%): | 0.656 |
30% Bioavailability (F30%): | 0.966 |
Blood-Brain-Barrier Penetration (BBB): | 0.006 | Plasma Protein Binding (PPB): | 98.61% |
Volume Distribution (VD): | 0.495 | Fu: | 4.04% |
CYP1A2-inhibitor: | 0.033 | CYP1A2-substrate: | 0.918 |
CYP2C19-inhibitor: | 0.01 | CYP2C19-substrate: | 0.071 |
CYP2C9-inhibitor: | 0.066 | CYP2C9-substrate: | 0.131 |
CYP2D6-inhibitor: | 0.004 | CYP2D6-substrate: | 0.141 |
CYP3A4-inhibitor: | 0.031 | CYP3A4-substrate: | 0.15 |
Clearance (CL): | 1.04 | Half-life (T1/2): | 0.863 |
hERG Blockers: | 0.029 | Human Hepatotoxicity (H-HT): | 0.226 |
Drug-inuced Liver Injury (DILI): | 0.982 | AMES Toxicity: | 0.524 |
Rat Oral Acute Toxicity: | 0.039 | Maximum Recommended Daily Dose: | 0.482 |
Skin Sensitization: | 0.961 | Carcinogencity: | 0.516 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.91 |
Respiratory Toxicity: | 0.039 |